Bridge the Gap—SYNGAP Education and Research Foundation Presents Their First Research Grant to


Bridge the Gap – SYNGAP Education and Research Foundation presented Texas Children’s Hospital with their first research grant of $25,000.

Houston, Texas - September 17, 2018 - Bridge the Gap — SYNGAP Education and Research Foundation presented Texas Children’s Hospital with their first research grant of $25,000, taking place at The Mark A. Wallace Tower in the Bluebird Clinic of Neurology on September 10, 2018. The award was presented by Monica Weldon, President/CEO to Jimmy Holder, MD PhD, who is the lead director of the center and serves as the foundations Scientific Advisory Boards Chairman.

Texas Children’s is the first of two Centers of Excellence established within the last year. The other is located at Kennedy Krieger Institute in Baltimore, MD. The funding for this grant will go to help support projects, including a biomarker study that will aid in preparing for pre-clinical trial design as they move forward towards finding possible treatments for patients with SYNGAP1 mutations.

SYNGAP1 — related non-syndromic intellectual disability (NSID) in humans was first reported in 2009. A mutation in SYNGAP1 results in intellectual disability ranging from mild to severe, epilepsy and a multitude of other comorbidities. There can be associated attention deficits, impulsivity, and/or mood disorders. 94% - 100% of the SYNGAP1 patients have some type of epilepsy. SYNGAP1 is one of the top two single gene mutations being researched worldwide linked to autism. It also plays an important role in brain plasticity and may represent one of the most common causes of ID worldwide. The use of genomic sequencing has dramatically increased the capacity of physicians to identify these mutations.

About Bridge the Gap — SYNGAP Education and Research Foundation

Bridge the Gap — SYNGAP Education and Research Foundation (501(c) 3) is a non-profit organization whose mission is to serve, educate and fund research for families coping with the effects of SYNGAP1 mutations. The leading organization advocating and raising funds for research and treatments for SYNGAP1. Bridge the Gap-SYNGAP Education and Research Foundation’s mission is to improve the quality of life for people affected by SYNGAP1, provide family support, accelerating research and raising awareness.

About Texas Children’s Hospital

Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose mission is to create a healthier future for children and women throughout our global community by leading in patient care, education and research. We are proud to be consistently ranked among the top children’s hospitals in the nation.

Related Videos
Signs and Symptoms of Connective Tissue Disease
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
© 2024 MJH Life Sciences

All rights reserved.